Yan Peng, M.D., Ph.D. Titles and Appointments Professor Schools Medical School Departments Pathology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Dr. Yan Peng, MD, PhD, completed her pediatric residency and served as chief resident at Beijing Medical University (Peking University Health Science Center), where she subsequently practiced as a pediatric nephrologist for two years. She then pursued six years of basic science research in kidney disease at the Mayo Clinic in Rochester and UT Southwestern Medical Center (UTSW). Following this, she completed a pathology residency at the University of Pittsburgh Medical Center (UPMC). She went on to complete two ACGME-accredited fellowships in Breast and Gynecologic Pathology at UPMC and in Cytopathology at BIDMC/Harvard Medical School. Dr. Peng joined the pathology faculty at UTSW in 2005. Dr. Peng is a surgical pathologist and cytopathologist with extensive expertise in breast and gynecologic pathology, and cytopathology and certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology and Cytopathology. In 2009, she became the inaugural co-leader of the specialized breast pathology service in university hospitals. Since 2012, she has served as the pathology representative on the Cancer Committee of the National Cancer Institute (NCI)-designated Simmons Comprehensive Cancer Center at UTSW. She also served for 10 years as the founding medical director of both the Diagnostic Immunohistochemistry Laboratory and the Tumor Biomarker Image Analysis Laboratory at PHHS. Dr. Peng has participated as a clinical investigator in multiple NCI breast and gynecologic cancer clinical trials through the NCI Cancer Therapy Evaluation Program. She is also a co-investigator on several NIH R01-funded research projects focused on identifying novel therapeutic targets for breast cancer. Dr. Peng has authored/co-authored more than 100 peer-reviewed publications. She served as Editor of the textbook Practical Breast Pathology (Springer, 2019), as well as special issues on breast pathology for Seminars in Diagnostic Pathology (Elsevier, 2022) and Human Pathology (Elsevier, 2025). In addition, she has contributed multiple book chapters to breast pathology textbooks. She is the founding Deputy Editor-in-Chief of the Journal of Clinical and Translational Pathology (Xia & He Publishing Inc.) and has served as Section Editor for Gynecologic Pathology for Human Pathology Reports (Elsevier). She has also served on the editorial boards of several journals, including Cancers and Human Pathology. She is an invited reviewer for JNCCN, Cell Reports Medicine, Biomaterials, Cancer Treatment Reviews, and eBioMedicine. Dr. Peng has delivered numerous presentations on breast cancer at both national and international conferences. She is a former president of the North Texas Society of Pathologists. Dr. Peng has served on the University Faculty Promotion and Tenure Committee and has chaired the Pathology Faculty Mentoring Committee since 2018. She is also a past president of the UTSW Faculty Senate. Education Medical School Beijing Medical University (1986) Residency Beijing University Hospital (1989), Pediatrics Graduate School Beijing Medical University, China (1991) Other Post Graduate Training Beijing Medical University, China (1991) Fellowship Mayo Clinic College of Medicine (1995), Physiology Fellowship UT Southwestern Medical Center (1999), Molecular Nephrology Research Residency University of Pittsburgh Medical Center (2003), Anatomic & Clinical Pathology Fellowship University of Pittsburgh Medical Center Magee Womens Hospital (2004), Breast & Gynecologic Pathology Fellowship Harvard Medical School/Beth Israel Deaconess Medical Center (2005), Cytopathology Research Interest Breast Cancer and Gynecologic Cancer Pathology Diagnostic Immunohistochemistry: Theranostic and Genomic Applications Prognostic and predictive tumor biomarkers Publications Featured Publications Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. Palakurthi B, Fross SR, Guldner IH, Aleksandrovic E, Liu X, Martino AK, Wang Q, Neff RA, Golomb SM, Lewis C, Peng Y, Howe EN, Zhang S, Nat Commun 2023 Apr 14 1 2109 TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Wang J, Peng Y, Sun H, Aung PP, Resetkova E, Yam C, Sahin AA, Huo L, Ding Q, Arch Pathol Lab Med 2023 Apr Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer. Zhang H, Peng Y, Cancers (Basel) 2022 Dec 15 1 HER2-low breast cancers: Current insights and future directions. Zhang H, Karakas C, Tyburski H, Turner BM, Peng Y, Wang X, Katerji H, Schiffhauer L, Hicks DG, Semin Diagn Pathol 2022 Jul Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Liu X, Viswanadhapalli S, Kumar S, Lee TK, Moore A, Ma S, Chen L, Hsieh M, Li M, Sareddy GR, Parra K, Blatt EB, Reese TC, Zhao Y, Chang A, Yan H, Xu Z, Pratap UP, Liu Z, Roggero CM, Tan Z, Weintraub ST, Peng Y, Tekmal RR, Arteaga CL, Lippincott-Schwartz J, Vadlamudi RK, Ahn JM, Raj GV, Nat Cancer 2022 Jun Update on prognostic and predictive biomarkers of breast cancer. Hou Y, Peng Y, Li Z, Semin Diagn Pathol 2022 Jun Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, Lewis C, Peng Y, Bachoo RM, Arteaga CL, Hanker AB, DeBerardinis RJ, Malladi S, Cell Metab 2022 Jan 34 1 90-105.e7 The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer. He L, Wick N, Germans SK, Peng Y, Cancers (Basel) 2021 Dec 13 24 Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers. Challa S, Khulpateea BR, Nandu T, Camacho CV, Ryu KW, Chen H, Peng Y, Lea JS, Kraus WL, Cell 2021 Jul HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. He L, Araj E, Peng Y, Curr Oncol 2021 Apr 28 3 1608-1617 Results 1-10 of 67 1 2 3 4 5 Next Last Books Featured Books Invasive Breast Carcinomas. In Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.). Peng Y, Kong C, and Chen Y. (2013; 147-212). Philadelphia, PA, Elsevier Breast Pathology Special Issue of Seminars in Diagnostic Pathology (Ed.) (2022). Elsevier Breast Pathology Special Issue of Human Pathology (Ed.) (2025). Elsevier Practical Breast Pathology Yan Peng, Ping Tang (Ed.) (2019). New York, Springer Immunohistochemistry in Breast Cancer. In Practical Breast Pathology Ping Tang, Marilyn M. Bui, Yan Peng (2019). New York, Springer Breast Cancer with Hereditary Cancer Predisposition Syndromes. In Practical Breast Pathology Roshni Rao, Caitlin B. Mauer, Margaret Chen-Seetoo, Yan Peng (2019). New York, Springer Metastatic Tumors in the Breast. In Breast Pathology (Third Edition) Zaibo Li, David Dabbs, Yan Peng (2023). Philadelphia, PA USA, Elsevier Honors & Awards Faculty mentor (Breast and Gynecologic Pathology), United States and Canadian Academy of Pathology (USCAP) (2025) Guest EditorHuman Pathology (Elsevier), Breast Pathology Special Issue (2025) Faculty Mentor (Breast Pathology), United States and Canadian Academy of Pathology (USCAP) (2024) Invited Speaker: Best Clinical Practice in HER2 Testing Interpretation in the Era of HER2-directed Antibody Drug ConjugatesThe Ninth International Conference on Cancer Research & Drug Development (Cancer R&D), Boston, MA (2024) Invited Speaker: Updates in Breast Cancer Biomarkers in 2023The Eighth International Conference on Cancer Research & Drug Development (Cancer R&D), Boston, MA (2023) Top Doctor (Pathologist)Texas Magazine (2022) Founding Deputy Editor-in-Chief of the Journal of Clinical and Translational Pathology (Xia & He Publishing Inc.) (2021-2026) Session Chair, The Breast Pathology Platform Sessions for the United States and Canadian Academy of Pathology (USCAP) 110th annual meeting (2021) Outstanding peer reviewer for Human Pathology (one of leading pathology scientific journals in the US) (2018) Member, Abstract Review Board of United States and Canadian Academy of Pathology (Breast Pathology Category) (2017-2020) President, International Association of Chinese Pathologists (2017-2018) President, UT Southwestern Faculty Senate (2017-2018) Finalist for Best Scientific Abstract Award of American Society for Clinical Pathology (senior mentor) (2015) Distinguished Young Investigator Award in MedicineBeijing, China (1993) Distinguished Scientist Award of Canada China Child Health Foundation (1992) Best National Medical Article AwardChina (1991) Invited Speaker: 2025 Updates on Breast Cancer Biomarkers in Clinical Practice. Chair of Targeted Therapy SessionThe Tenth International Conference on Cancer Research & Drug Development, Boston, MA (2025)
